Increase in demand from healthcare sector drives the demand for
inhaled nitric oxide. However, strict application norms across various
geographical regions may restraint the growth in the future. Ongoing R&D
activities leading to new application areas in healthcare industry present a
major opportunity for Inhaled Nitric Oxide
Market expansion.
Download PDF Report
Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/3020
Nitric oxide or NO is a colorless and odorless gas partially
soluble in water. Inhaled nitric oxide is used for the treatment of several
respiratory associated diseases.
The report segments the global inhaled nitric oxide market on
the basis of application and geography. On the basis of application, it is classified
into neonatal respiratory treatment, chronic obstructive pulmonary disease
(COPD), malaria treatment, tuberculosis treatment, acute respiratory distress
syndrome (ARDS), chronic wound healing, and others. Geographically, it is
analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market
players, such as Nu-Med Plus, Inc., GENOSYS Inc., Praxair, Inc., Air Liquide
S.A., Mallinckrodt Pharmaceuticals, Sigma-Aldrich Co. LLC., Novoteris, LLC,
Ikaria Canada Inc., GeNO, LLC., and Perma Pure LLC, are also provided in the
report.
Key Benefits
- This report provides a
quantitative analysis of the current trends and estimations from 2017 to
2023 of the global inhaled nitric oxide market to identify the prevailing
market opportunities.
- Major countries in each region are
mapped according to individual market revenue.
- Comprehensive analysis of factors
that drive and restrict the market growth is provided.
- The report includes an in-depth
analysis of current research & clinical developments within the market
with key dynamic factors.
- Key players and their key
developments in the recent years are listed.
No comments:
Post a Comment